Metabolism-Based Blood Test to Detect Multiple Cancer Types Prior to Symptoms
|
By LabMedica International staff writers Posted on 22 Jun 2022 |
|
A pioneering metabolism-based liquid biopsy could detect any-type cancer in adults who show no symptoms or have any recent history of cancer, thereby preventing cancer mortality through early detection.
Elypta (Stockholm, Sweden), which aims to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, will develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence in kidney cancer patients. The tests are based on the exhaustive profiling of human glycosaminoglycans - also known as the GAGome - as biomarkers of cancer metabolism, an approach pioneered by Elypta.
Metabolic reprogramming is a hallmark of cancer. Cancer cells need to rewire the way they procure energy and nutrients to support abnormal proliferation and growth. Yet, metabolism is an under-investigated layer of information to identify biomarkers for cancer. By overlaying genome-wide omics data onto the largest reconstruction of the human metabolic network, Elypta identified the profile of the GAGome as the most deregulated panel of metabolites in cancer.
Recent evidence suggests that metabolic reprogramming of GAGomes is a ubiquitous process in cancers. In a clinical study with over 1500 samples across 14 cancer types, a multi-cancer GAGome signature was detected in the plasma and urine that was significantly elevated already in stage I in every cancer type tested. Preclinical evidence in mice supports a causal link between cancer initiation and changes in the GAGome providing mechanistic insight on its value for early detection.
“Our MCED test has the potential to greatly increase the share of cancers detected at the earliest stages when treatment could mean a cure besides being less costly,” said Francesco Gatto, CSO & Founder of Elypta. “Detecting stage I cancer is the key challenge here, and whereas other MCED tests based on cell free DNA struggle to find cancer at this early stage, metabolism-based biomarkers could really make a difference.”
Related Links:
Elypta
Latest Molecular Diagnostics News
- Urine Test Detects Early Stage Pancreatic Cancer
- Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
- Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients
- Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
- Mitochondrial DNA Mutations from Kidney Stressors Could Predict Future Organ Decline
- Blood Test Could Predict Bariatric Surgery Outcomes in Teenagers
- ctDNA Blood Test to Help Personalize Postsurgical Colon Cancer Treatment
- AI Powered Blood Test Predicts Suicide Risk in Bipolar Patients
- DNA Sensor Enables Molecular Detection from Single Blood Drop
- DNA-Powered Test Accurately Detects E. Coli Lookalike Bacteria
- World’s Fastest DNA Sequencing Technique to Revolutionize NICU Genomic Care
- Blood Test Uses Cell-Free DNA to Detect ALS Faster and More Accurately
- Multi-Cancer Early Detection Blood Test Increases Cancer Detection
- Portable Label-Free Device Tracks Alzheimer's Disease in Real Time
- Liquid Biopsy Test Enables Early Detection of ICI-Related Myocarditis
- Rapid POC Diagnostic Test Detects Asymptomatic Malaria Cases
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Hematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Immunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read more
Microbiology
view channel
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Sepsis is a life-threatening condition that occurs when the body’s response to infection spirals out of control, damaging organs and leading to critical illness. Patients often arrive at intensive care... Read more
Pathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read more
Technology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read more
Industry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more
